HNF-4α determines hepatic differentiation of human mesenchymal stem cells from bone marrow

Mong-Liang Chen, Kuan-Der Lee, Huei-Chun Huang, Yue-Lin Tsai, Yi-Chieh Wu, Tzer-Min Kuo, Cheng-Po Hu, Chungming Chang

Abstract

AIM: To investigate the differentiation status and key factors to facilitate hepatic differentiation of human bone-marrow-derived mesenchymal stem cells (MSCs).

METHODS: Human MSCs derived from bone marrow were induced into hepatocyte-like cells following a previously published protocol. The differentiation status of the hepatocyte-like cells was compared with various human hepatoma cell lines. Overexpression of hepatocyte nuclear factor (HNF)-4α was mediated by adenovirus infection of these hepatocyte-like cells. The expression of interesting genes was then examined by either reverse transcription-polymerase chain reaction (RT-PCR) or real-time RT-PCR methods.

RESULTS: Our results demonstrated that the differentiation status of hepatocyte-like cells induced from human MSCs was relatively similar to poorly differentiated human hepatoma cell lines. Interestingly, the HNF-4 isoform in induced MSCs and poorly differentiated human hepatoma cell lines was identified as HNF-4γ instead of HNF-4α. Overexpression of HNF-4α in induced MSCs significantly enhanced the expression level of hepatic-specific genes, liver-enriched transcription factors, and cytochrome P450 (P450) genes.

CONCLUSION: Overexpression of HNF-4α improves the hepatic differentiation of human MSCs from bone marrow and is a simple way of providing better cell sources for clinical applications.

© 2010 Baishideng. All rights reserved.

Key words: Bone marrow; Cytochrome P450 genes; Differentiation of hepatocyte; Hepatocyte nuclear factor 4; Human mesenchymal stem cells

Peer reviewers: Dr. Fabio Marra, Dipartimento di Medicina Interna, University of Florence, Viale Morgagni, 85, I-50134 Florence, Italy; Sharon DeMorrow, Assistant Professor, Division of Research and Education, Scott and White Hospital and The Texas A&M University System, Health Science Center College of Medicine, Temple, TX 76504, United States; Ekihiro Seki, MD, PhD, Department of Medicine, University of California San Diego, Leichag Biomedical Research Building Rm 349H, 9500 Gilman Drive MC#0702, La Jolla, CA 92093-0702, United States

Chen ML, Lee KD, Huang HC, Tsai YL, Wu YC, Kuo TM, Hu CP, Chang C. HNF-4α determines hepatic differentiation of human mesenchymal stem cells from bone marrow. World J Gastroenterol 2010; 16(40): 5092-5103 Available from: URL: http://www.wjgnet.com/1007-9327/full/v16/i40/5092.htm DOI: http://dx.doi.org/10.3748/wjg.v16.i40.5092
INTRODUCTION

The liver is an important organ and performs many biological functions, such as plasma protein synthesis, glucose and fatty acid metabolism, and detoxification. The standard treatment for irreversible liver failure has been focused on liver transplantation; however, the availability of donor tissues is limited and enables only 10% of candidate patients to receive transplants. Recently, hepatocyte transplantation or bioartificial livers have become promising alternatives for treatment\cite{12}, but the development of cell-based therapies is hindered by the propagation of hepatocytes and the maintenance of their hepatic functions in vitro. Therefore, it would be of great benefit to develop in vitro models of hepatocyte differentiation to facilitate future clinical applications.

Recently, success in driving stem cells into hepatic lineage has provided great hope for overcoming the limitation of cell sources for hepatocyte transplantation\cite{1-3}. Previous studies have demonstrated that reservoirs of stem cells may reside in several types of adult and fetal tissues, including liver stem cells as a hepatic source and embryonic stem cells, bone marrow cells, and umbilical cord blood cells as a non-hepatic source. Most of these cells can be induced toward hepatic differentiation and to exhibit hepatic functions in both in vivo and in vitro systems\cite{7-9}. Among them, the study of hepatic differentiation of bone marrow cells is most attractive because the autologous stem cells can be easily isolated, expanded extensively, and induced into hepatic differentiation for transplantation back into the patient. It has been reported that mesenchymal stem cells (MSCs) derived from bone marrow have the potential to differentiate into cells of mesodermal lineage, such as osteoblasts, chondrocytes, and adipocytes, as well as into various types of cells of other lineages, including neural and liver cells\cite{10}. Furthermore, the hepatic differentiation of MSCs in vitro has been established in rat and mouse models\cite{11-13}. These observations bring new hope for the possible application of cell-based therapy in severe liver diseases. However, the hepatic differentiation status of hepatocyte-like cells derived from stem cells is not sufficient for clinical use because the relatively low expression levels of drug metabolizing enzymes and their metabolic activities are not fully induced\cite{10}. Therefore, it is important to develop a simple strategy for the efficient induction of hepatic differentiation.

The coordinated expression of various liver-specific genes is required for hepatic differentiation and the biological functions of adult liver. Previous studies have demonstrated that most hepatic gene expression is regulated primarily through the combinatorial action of several liver-enriched transcription factors\cite{15-17}. Among them, hepatocyte nuclear factor (HNF)-4α plays a crucial role in the liver-specific phenotype through induction of various liver-specific functions\cite{18}. Several studies have demonstrated that HNF-4α may act as a master gene in a transcription factor cascade that could drive hepatic differentiation\cite{19,20}. These studies suggest that high expression of HNF-4α may be a simple strategy for the induction of hepatic differentiation and the functions of hepatocyte-like cells derived from stem cells in the cell culture system.

In this study, we demonstrated that human bone marrow MSCs can be differentiated into hepatocyte-like cells according to the procedure established by Lee et al\cite{3}. Furthermore, overexpression of a single liver-enriched transcription factor, HNF-4α, could significantly improve the differentiation status of hepatocyte-like cells through activation of several target genes. Apparently, these more differentiated hepatocyte-like cells will provide a better cell source for future clinical applications and in vitro hepatotoxicity models for drug screening.

MATERIALS AND METHODS

Propagation of human bone marrow MSCs

Human bone marrow MSCs were isolated and characterized by Lee et al\cite{3}. Briefly, human bone marrow was collected from healthy donors with informed consent and approved by the institutional review board of the Taipei Veterans General Hospital. Mononuclear cells were obtained by negative immunodepletion of CD3, CD14, CD19, CD38, CD66B, and glycophorin-A positive cells using a commercially available kit (RosetteSep, StemCell Technologies) according to the manufacturer’s instructions, followed by Ficoll-Paque density-gradient centrifugation (1.077 g/cm³), and plated in tissue culture plates in expansion medium. The expansion medium consisted of Iscove’s modified Dulbecco’s medium (IMDM) (Gibco) and 10% fetal bovine serum (Hyclone) supplemented with 10 ng/mL epidermal growth factor (EGF) (Becton Dickinson) and 10 ng/mL basic fibroblast growth factor (bFGF) (R&D Systems). The adherent cells were amplified within the expansion medium until hepatic induction.

Hepatic differentiation of human MSCs

The hepatic induction of human bone marrow MSCs was performed according to the protocol developed by Lee et al\cite{3}. In brief, 5th- to 13th-passage stem cells (at 1.0 to 1.3 × 10⁶/cm²) were serum deprived for 2 d in IMDM supplemented with 20 ng/mL EGF and 10 ng/mL bFGF prior to induction using a two-step protocol. Differentiation was induced by treating MSCs with step-1 differentiation medium, consisting of IMDM supplemented with 20 ng/mL hepatocyte growth factor (R&D Systems), 10 ng/mL bFGF and 0.61 g/L nicotinamide for 7 d, followed by treatment with step-2 maturation medium, consisting of IMDM supplemented with 20 ng/mL oncostatin M (R&D Systems), 1 μmol/L dexamethasone (Sigma), and 50 mg/mL ITS+ premix (Becton Dickinson). Medium changes were performed twice weekly.

Cell culture

Human hepatoma cell lines HepG2\cite{21}, HA22T/VGH\cite{22} and SK-Hep-1\cite{23} were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) containing 10% fetal calf serum (Gibco) as described previously\cite{24,25}.
Table 1  Primer sets used for reverse transcription-polymerase chain reaction analysis

| Gene     | Forward primer | Reverse primer | Product size (bp) |
|----------|----------------|----------------|-------------------|
| Alb      | TGCTGAAATGCGCTGATGACGG | AAGCCAGTCAAGCCATCTCACT | 161 |
| AFP      | TGCCAGCAATGAGAGGAGGGAAGA | CATTACGACAGCCCACCAAGAAGA | 216 |
| TAT      | TGAGCTCTGCTCATCGTCTCCGCA | TATGGTTCATCTGCTGATC | 338 |
| G6P      | CGCTGCTCATCGTCTGCTGCTCAG | TACTGGAGATGATGACCTG | 350 |
| TO       | ATACAGACCTGCTGCTGACCTGAC | TGGTTCAGCTTCCGCGTATC | 358 |
| HNF-1a   | GTGTCTCACAAGCTGGGACCC | TGTAGCATCTGACGTTGAG | 299 |
| HNF-3β   | CACCATCAGCGCTCAACCC | GTTATGAGATGATGACCTG | 251 |
| HNF-4     | CTCTCCGAGCCACAAAAGAGATCCATG | ATCTACGACAGCCCACCAAGAAGA | 235 |
| C/EPBα   | CAAGAACTCGCTGAGCAGACAC | CTTGCTTACTAGCCACCAAG | 371 |
| β2M      | TGAGCTGCTGAGCAGGACCTG | TGGGAGACAGCAGCAGCAGC | 450 |

The thermo-cycling parameters for β2M: 94°C for 5 min/28 cycles of 94°C for 30 s, 56°C for 30 s, and 72°C for 30 s/72°C for 10 min; The thermo-cycling parameters for other genes: 94°C for 5 min/38 cycles of 94°C for 30 s, 56-58°C for 30 s, and 72°C for 30 s/72°C for 10 min. Alb: Albumin; AFP: α-fetoprotein; TAT: Tyrosine-amino-transferase; TO: Tryptophan 2,3-dioxygenase; G6P: Glucose 6-phosphatase; β2M: β-2-microglobulin.

Table 2  Primer sets for real-time reverse transcription-polymerase chain reaction analysis

| Gene     | Forward primer | Reverse primer | Probe |
|----------|----------------|----------------|-------|
| HNF-1a   | TGAGCTCCGGGCGCTCAGC | GCAGTCTGCTGAGGACCTG | 42   |
| HNF-3β   | GCCATTGGCAGATTGAGTGT | GACCTGCTGACGCTGACG | 25   |
| HNF-4α   | ATTCGACATTGCTGGAGCA | CGTCAGCTGGCATCTGAC | 77   |
| HNF-4γ   | GTTGCATCAGCCAGATGCT | AGCTGCTGAGGCTGACG | 8    |
| HNF-6    | CCTGGGACCAACTCATACCC | TCTGCTGTGGGACGTAAC | 88   |
| C/EPBα   | CAAGACTCTGATGATGACCTG | CGGAGAAAACCAAAAACAA | 3    |
| PPARα    | GGTCCGGCAGATTTCTCATAT | GAAGCTGCTGCTGACGTAAC | 14   |
| Alb      | TGTTGCGAAGCTCGCTGATA | CTTGCTCGGAGATTGTGAC | 27   |
| TAT      | TCTGCTGACAGCTATCACCT | CTGTCAGCCAGACTTCGCT | 67   |
| G6P      | GTTCTCACATTTCTCATCACA | TCTGCTGACAGCTATCCTG | 67   |
| CYP1A1   | GAGCAGATCCATCGCTGCT | CAAATGTGCTGCTGACG | 80   |
| CYP1A2   | CAAGAAATGCTGCTGCTGCTA | AGGGAGTCGGCTCCACAG | 59   |
| CYP2A6   | CAAAAGAGAACCAAGATTCCTG | AGGCGCGATGCTGCTGACG | 35   |
| CYP2B6   | GAAGCTTCTTTCTTCCCAT | GCCATTGACAGATGATGACG | 35   |
| CYP2C8   | AAGAAGAATGACTACTTCTCCGCTT | CAAATGGCTTCTGCTGACG | 18   |
| CYP2C9   | ATTCGACATTTCTCATCACA | CAGGGAAATATATAGTGGTGC | 43   |
| CYP2C19  | GTCCAGAGATCAATGCTGCTC | AGTGGAGGAGATTATATAGTGGTGC | 43   |
| CYP2C26  | AGGAGAGTGGCGGCCTTCTC | CGTCAGGATGCCAGG | 56   |
| CYP2E1   | CAGACGTTCTCCACACGAGA | CAACAAAGAACAAACACTCCCATC | 67   |
| HPRT     | AGGGTTGGCGGAGGAAA | AGCCACCGGAGAAAACAA | 59   |

The thermo-cycling parameters for real-time reverse transcription-polymerase chain reaction analysis: 95°C for 10 min/50 cycles of 95°C for 10 s, 60°C for 30 s, and 72°C for 1 s/40 cycles for 30 s. Alb: Albumin; AFP: α-fetoprotein; TAT: Tyrosine-aminotransferase; G6P: Glucose 6-phosphatase; PPARα: Peroxisome proliferator-activated receptor α; HPRT: Hypoxanthine-guanine phosphoribosyltransferase.

Immunofluorescence
To stain for albumin, cells were fixed with 4% paraformaldehyde at 4°C, and permeabilized with 0.1% Triton X-100 for 15 min. The slides were incubated with mouse monoclonal antibodies against human albumin (Santa Cruz) (1:50 dilution) for 1 h, followed by fluorescein-conjugated goat anti-mouse antibody (Jackson ImmunoResearch) (1:100 dilution) for 1 h. Hoechst stain was used for labeling DNA. Between incubations, samples were washed with phosphate-buffered saline (PBS).

Uptake of low-density lipoprotein
The Dil-Ac-low-density lipoprotein (LDL) staining kit was purchased from Biomedical Technologies and the assay was performed following the manufacturer's instructions.

Reverse transcription-polymerase-chain-reaction and real-time reverse transcription-polymerase-chain-reaction analysis
Total RNA was isolated from induced MSCs using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. The cDNA templates were obtained by reverse transcription of total RNA with oligo(dT) 18-mers and Superscript reverse transcriptase (Invitrogen). The products were then subjected to either reverse transcription-polymerase chain reaction (RT-PCR) analysis with the specific primer pairs and conditions listed in Table 1 or quantitative real-time RT-PCR analysis with the specific primer pairs and Taqman probes listed in Table 2 (according to the instruction of the Assay Design Center, Universal ProbeLibrary System, Roche Applied Science).
Recombinant adenoviruses

The HNF-4α expression vector (Ad/HNF4α-IRES-EGFP) contained the rat HNF-4α cDNA fragment (kindly provided by Dr. Ou JH) in the parental adenovirus vector (Ad-IRES-EGFP) which was constructed based on the Adeno-X expression system (Clontech) containing the internal ribosome entry site (IRES) of the encephalomyocarditis virus and EGFP gene. The adenoviruses were packaged and amplified in 293 cells and then purified by banding on CsCl gradients. The titer of recombinant adenoviruses was estimated according to the amount of viral genome. The 8w-induced MSCs were infected with purified adenoviruses at a 1500 multiplicity of infection (m.o.i) for 1 h in serum-free medium. The overexpression of HNF-4α was confirmed by real-time RT-PCR (forward primer: CAAGAGGTCCATGGTGTTCA; reverse primer: CCGAGGGACGATGTAGTCA; Taqman probe: #68). For the induction of P450 genes, 50 μmol/L of B-naphthoflavone or rifampicin (Sigma) was added to the culture medium for 2 d.

Statistical analysis

Statistical significance for the induction effect was determined by t-test. Differences were considered significant if the P value was less than 0.05.

RESULTS

The differentiation status of hepatocyte-like cells induced from human bone marrow MSCs

Human MSCs were isolated from bone marrow, expanded in growth medium, and differentiated into hepatic lineage according to the protocols previously described by Lee et al. Under hepatic induction conditions, the fibroblastic morphology of MSCs (Figure 1A, 0 wk and 1 wk) gradually proceeded toward the polygonal shape of hepatocytes with the appearance of abundant granules in the cytoplasm (Figure 1A, 4 wk, 7 wk, and 10 wk). Interestingly, compared with human hepatoma cell lines of different differentiation status-HepG2, HA22T/VGH, and SK-Hep-1 cells; the morphology of induced MSCs at an early stage was similar to that of spindle-shaped SK-Hep-1 and HA22T/VGH cells. After 7 wk of induction, the morphology of MSCs gradually approached that of HepG2 cells (Figure 1B). These observations suggest that the induction of the differentiation process of human MSCs may have some similarities to human hepatoma cell lines with different stages of differentiation.

Beside the morphological differences, we also evaluated biological properties to characterize the hepatic maturation of induced MSCs including uptake of low-density lipoprotein (LDL) and albumin expression. After 10 wk of induction, most of the induced MSCs exhibited positive signals for albumin expression (Figure 1C) and LDL uptake (Figure 1D). These results also demonstrated that human MSCs have the potential to differentiate into hepatocyte-like cells as previously described.

Furthermore, to compare the differentiation status of human MSCs at a different period of induction with human hepatoma cell lines, the expression pattern of several hepatic genes was investigated using RT-PCR in human MSCs induced at 0, 1, 4, 7, and 10 wk together with HepG2, HA22T/VGH, and SK-Hep-1 cells (Figure 2). These hepatic genes included (1) an indicator for the early hepatic gene, albumin (Alb); (2) indicators for the middle hepatic gene, tyrosine-amidotransferase (TAT), and glucose 6-phosphatase (G6P); (3) indicators for the late hepatic gene, tryptophan 2,3-dioxygenase (TO) and (4) liver-enriched transcription factors including HNF-1α, HNF-3β, HNF-4, and C/EBPα. Our data indicated that most of the detected genes, including Alb, TAT, TO, HNF-3β, HNF-4, and C/EBPα, were expressed in MSCs 10 wk after induction, whereas the immature marker alphafetoprotein was not expressed during the entire period of induction (Figure 2A). Among them, the Alb gene was expressed as early as serum starvation treatment and maintained its expression during the whole induction period. The TAT gene was induced to be expressed 1 wk post-induction and the TO gene was activated 4 wk post-induction. This unique pattern is similar to the sequential expression of hepatic genes during hepatocyte maturation. However, the expression of G6P was not detectable, even 10 wk after induction. The expression of liver-enriched transcription factors HNF-4 and C/EBPα was also activated 4 wk after induction. In contrast, HNF-3β was only weakly expressed until 7 wk post-induction and HNF-1α was not expressed 10 wk after induction. In the human hepatoma cells (Figure 2B), all genes except for TO were well expressed in HepG2 cells; Alb, TO, and HNF-4 genes were expressed in HA22T/VGH cells; and TAT, TO, HNF-3β, HNF-4, and C/EBPα genes were expressed in SK-Hep-1 cells. In general, the expression level of investigated hepatic genes was much lower in the hepatocyte-like cells derived from human MSCs than those in HepG2 cells, the well-differentiated hepatoma cell line, and relatively better than those in poorly differentiated hepatoma cell lines HA22T/VGH and SK-Hep-1. Taken together, human bone marrow MSCs can be specifically induced toward hepatic lineage and expressed certain hepatic-specific genes and liver-enriched transcription factors. However, the expression potency of hepatic genes was weak compared with well-differentiated hepatoma cells. Our results suggested that the differentiation status of induced MSCs seems to lie between the well-differentiated and poorly differentiated cell types of human hepatoma cell lines.

To confirm the specificity of these RT-PCR analyses, we performed a sequence analysis of the PCR fragments followed by nucleotide BLAST analysis. Interestingly, we found that the sequence of the PCR fragments from induced MSCs, HA22T/VGH, and SK-Hep-1 cells corresponded to the HNF-4γ gene, which is not expressed in adult liver, and that from HepG2 cells corresponded to the HNF-4α gene (data not shown). These results revealed that HNF-4α was only expressed in HepG2 cells, whereas HNF-4γ was expressed in the induced MSCs, HA22T/VGH and SK-Hep-1 cells. To further study the
kinetic expression of HNF-4, we use real-time RT-PCR analysis with specific isoform primers (Table 2) to estimate the expression level of HNF-4α or HNF-4γ in these samples. Similarly, expression of the HNF-4γ gene was

Figure 1 Hepatic differentiation of human bone marrow-derived mesenchymal stem cells. A: Morphological characterization of differentiated mesenchymal stem cells (MSCs) under hepatic induction. 0 wk: Undifferentiated MSCs; 1 wk: 1 wk post-induction; 4 wk: 4 wk post-induction; 7 wk: 7 wk post-induction; and 10 wk: 10 wk post-induction (original magnification, × 50); B: Morphology of human hepatoma cell lines: SK-Hep-1, HA22T/VGH, and HepG2 (original magnification, × 100); C: Production of albumin (green color) in differentiated MSCs after 10 wk induction (10 wk) and counterstained with Hoechst (blue color). The undifferentiated MSCs (0 wk) were used as negative control cells (original magnification, × 200); D: Uptake of low-density lipoprotein (red color) in differentiated MSCs after 10 wk induction (10 wk). The undifferentiated MSCs (0 wk) were used as negative control cells (original magnification, × 100).
gradually increased during the hepatic induction of MSCs, and HA22T/VGH as well as SK-Hep-1 cells (Figure 3A). In contrast, the HNF-4α gene was not expressed during the hepatic induction of MSCs, whereas it was significantly expressed in HepG2 cells (Figure 3B). These results suggested that the hepatic induction of human MSCs in this study was not efficient because of the failed expression of HNF-4α during the induction process.

Enhancement of hepatic differentiation by overexpression of HNF-4α

Several studies have demonstrated that hepatic gene expression is regulated by the combinational action of liver-enriched transcription factors. In this study, we found that the expression of HNF-3β and C/EBPα was significantly weaker than that of well-differentiated hepatocytes in induced MSCs for 10 wk. Furthermore, the expression of HNF-1α and HNF-4α was undetectable in these cells. Our results clearly indicated that the induced MSCs were not well differentiated because of the low expression of these liver-enriched transcription factors. Among them, HNF-4α is crucial for hepatic differentiation because it exhibits a central determinant of hepatic gene expression including liver-enriched transcription factors. Therefore, we investigated whether the transcription efficiency of hepatic genes could be simply activated by HNF-4α overexpression in induced MSCs and further improve their differentiation status. Overexpression of the rat HNF-4α gene was introduced into 8w-induced MSCs by adenovirus-mediated gene transfer (Ad/HNF4α-IRES-EGFP). Most of the cells (more than 80%) were successfully infected at a 1500 m.o.i. as monitored by the coexpressed EGFP gene, and the overexpression of HNF-4α was confirmed by real-time PCR analysis (Figure 4A). The expression level of other liver-enriched transcription factors in the HNF-4α-infected cells was examined by real-time RT-PCR analysis and compared with that of mock control cells infected with control adenoviruses (Ad-IRES-EGFP) (Figure 4B).
The expression of HNF-1α, C/EBPα, and peroxisome proliferator-activated receptor α (PPARα) was induced 3- to 7-fold in the HNF-4α-infected hepatocyte-like cells. Furthermore, the expression of HNF-3β and HNF-6 was dramatically induced by more than 100-fold (500-fold and 100-fold, respectively) in the HNF-4α-infected hepatocyte-like cells. The effect of HNF-4α overexpression on the induction of hepatic-specific genes was also evaluated by the same method. Among them, expression of Alb, TAT, and G6P genes was markedly induced in HNF-4α-infected cells, compared with mock control cells, by 12-, 40-, and 2000-fold, respectively (Figure 5).

**Induction of the P450 gene family by HNF-4α overexpression**

The drug-metabolizing enzymes, cytochrome P450 enzymes, are a superfamily of monooxygenases that play an important role in the detoxification of xenobiotics and the metabolic activation of chemical carcinogens in mature hepatocytes. Therefore, the expression of P450 genes is also designated as an indicator for the late hepatic genes. In this study, the expression patterns of P450 genes, including CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4, were examined in induced MSCs, which were induced for 8 wk and then infected with Ad/HNF4α-IRES-EGFP for 1 wk, and compared with that in the mock control cells.
HNF-4 induces hepatic differentiation

Figure 5 Detection of liver-specific genes in hepatocyte nuclear factor-4α overexpressing induced mesenchymal stem cells by real-time reverse transcription-polymerase chain reaction. The induced mesenchymal stem cells (8 wk post-induction) were infected with adenovirus containing rHNF-4α gene (indicated as AdIEHNF4) or parental control adenovirus (indicated as AdIE). The relative level of each gene in the control group was set to 1. The induction effect of HNF-4α on the expression of liver-specific genes was represented as Albumin, tyrosine-aminotransferase (TAT), and glucose 6-phosphatase (G6P), respectively. The amount of input RNA was normalized using the hypoxanthine-guanine phosphoribosyltransferase gene. Each column represents the mean ± SD of three independent experiments and the induction fold for each gene was significant (P < 0.05). HNF: Hepatocyte nuclear factor.
infected with Ad-IRES-EGFP. As shown in Figure 6, most of the detected genes were not expressed in the induced MSCs (indicated as AdIE). However, all of the detected genes were significantly activated by the overexpression of HNF-4α (indicated as AdIE/HNF4). Among them, CYP1A1, CYP1A2, and CYP2C19 genes were markedly activated by more than 100-fold (Figure 6A); CYP2B6, CYP2C9, and CYP3A4 genes were markedly activated by more than 10-fold (Figure 6B); and CYP2A6, CYP2C8, CYP2D6, and CYP2E1 genes were moderately activated by 3- to 6-fold (Figure 6C).

It is well known that expression of P450 genes can be activated by a range of chemicals [28]. Therefore, the induction potential of P450 gene expression was also investigated after cells were incubated for 48 h with either B-naphthoflavone (BNF) or rifampicin (RIF), which are reported to be inducers of selective P450 genes [29]. As shown in Figure 6, the inducibility of P450 genes was observed in the presence of BNF or RIF both in induced MSCs (indicated as AdIE/b or AdIE/HNF4/b) and in HNF-4α-overexpressing cells (indicated as AdIEHNF4/b or AdIEHNF4/R). Among them, CYP1A1, CYP1A2, CYP2A6, CYP2C9, CYP2D6, and CYP2E1 genes were significantly activated by BNF; whereas CYP2A6, CYP2C9, CYP2C19, and CYP2E1 genes were significantly induced by RIF (P < 0.05). However, the expression of CYP2C8 and CYP3A4 was not induced and that of CYP2B6 was reduced by either BNF or RIF. Taken together, in the presence of a high amount of HNF-4α, the MSCs-derived hepatocyte-like cells can be further induced toward a more differentiated hepatocytic status. The expression of liver-specific genes, liver-enriched transcription factors, and P450 genes could be significantly activated by HNF-4α overexpression and move toward that of well-differentiated cell types.

**DISCUSSION**

Recently, several sources of stem cells have been successfully driven to hepatic differentiation and display several hepatic functions such as LDL uptake, glycogen storage and albumin expression [3,5]. In this study, we induced the hepatic differentiation of human bone marrow MSCs according to the protocol previously described by Lee et al [3]. The expression pattern of hepatic genes in induced human MSCs seems to be correlated with the developmental pro-

---

**Figure 6** Detection of P450 genes in hepatocyte nuclear factor-4α overexpressing induced mesenchymal stem cells by real-time reverse transcription-polymerase chain reaction. The induced mesenchymal stem cells (8 wk post-induction) were infected with adenovirus containing rHNF-4α gene (indicated as AdIEHNF4) or parental control adenovirus (indicated as AdIE). The infected cells were further treated with inducer B-naphthoflavone (indicated as AdIE/b or AdIEHNF4/b) or rifampicin (indicated as AdIE/R or AdIEHNF4/R) for 2 d. The relative level of each gene in the control group was set to 1. The induction effect of HNF-4α and/or inducer on the expression of P450 genes is represented as (A) CYP1A1, CYP1A2, and CYP2C19; (B) CYP2B6, CYP2C9, and CYP3A4; (C) CYP2A6, CYP2C8, CYP2D6, and CYP2E1, respectively. The amount of input RNA was normalized using the HPRT gene. Each column represents the mean ± SD of three independent experiments and the induction fold by HNF-4α overexpression for each gene was significant (P < 0.05). HNF: Hepatocyte nuclear factor.
cess of the liver in vitro. The differentiated cells expressed early hepatic genes as early as serum starvation treatment, middle hepatic genes at 1 wk post-induction, and late hepatic genes at 4 wk post-induction. However, their differentiation status was much less than that of HepG2 cells as evaluated by their potency of expression of hepatic-specific genes, liver-enriched transcription factors, and the P450 gene family. It is likely that the differentiation status of induced human MSCs lies between HepG2 cells and poorly differentiated hepatoma cells (HA22T/VGH and SK-Hep-1 cells).

It is well known that several liver-enriched transcription factors can coordinate the expression of hepatic genes that are involved in liver-specific functions[15,17]. Among them, HNF-4α may act as a master gene in the transcriptional cascade that regulates constitutive expression of target genes[18-20]. Interestingly, we found that one of the HNF-4 isoforms, HNF-4γ was expressed in the middle stage of induced MSCs and poorly differentiated hepatoma cell lines. The human HNF-4γ gene encodes for a 408 amino acid protein with 70% overall identity to human HNF-4α. A previous study revealed that HNF-4γ is expressed in the kidney, pancreas, small intestine, and colon but not in the liver, while HNF-4α is significantly expressed in the liver[21]. Studies also demonstrated that HNF-4γ is able to activate transcription through the same binding sites as HNF-4α, however, the transactivation potential of HNF-4γ is significantly less active than HNF-4α[30]. These results suggest that the poorly differentiated status of hepatocyte-like cells induced from human MSCs is likely due to the expression of HNF-4γ instead of HNF-4α. Moreover, we demonstrated that the differentiation status of hepatocyte-like cells derived from human MSCs could be further progressed toward that of well-differentiated HepG2 cells by adenovirus-mediated HNF-4α overexpression. Most of the detected hepatic genes, liver-enriched transcription factors, and P450 genes were significantly activated by HNF-4α overexpression. These findings indicate that HNF-4α plays a key role in facilitating hepatic differentiation of human MSCs derived from bone marrow and are consistent with previous studies in rodents[31,32].

Metabolism by cytochrome P450 is a major route of detoxification for a large number of xenobiotics. The induction of P450 gene expression is a common cellular defensive mechanism of hepatocytes against the toxicity of foreign compounds. Hepatic expression of P450 genes can be activated following exposure to various classes of inducers including B-naphthoflavone (BNF), rifampicin (RIF), and phenobarbital (PB)[29]. Among them, expression of CYP1A1 and 1A2 can be significantly induced by exposure to BNF, but weakly induced by RIF and PB[19,20]. Expression of CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, and CYP3A4 can be increased by RIF and PB, whereas CYP2D6 was not obviously induced by RIF or PB[29,34,35]. In this study, the inducibility of P450 genes by either BNF or RIF was also demonstrated in the hepatocyte-like cells and HNF-4α-overexpressing cells (Figure 6). In addition, we found that CYP2A6, CYP2C9, CYP2D6, and CYP2E1 genes can be activated by BNF, which had not been examined in previous studies. Relatively little or no induction of CYP2C8 and CYP3A4 or a reduction in CYP2B6 was shown in the presence of RIF. The reason for this observation is unknown at the present time and remains to be further investigated. Taken together, hepatic differentiation of stem cells in vitro can be improved by the ectopic expression of a single liver-enriched transcription factor such as HNF-4α.

In conclusion, HNF-4α is a key factor in determining the differentiation status of hepatocyte-like cells derived from human MSCs. Overexpression of HNF-4α can activate various hepatic-specific genes and enhance the differentiation status in differentiated MSCs. This may provide a simple and convenient way to obtain better cell sources for clinical applications and drug screening in vitro. Adenoviral vectors are efficient systems for gene delivery both in vivo and in vitro. However, several limitations including innate immune responses by host cells, genomic integration into target cells, and cytokotoxicity for target cells have impeded their clinical utility and studies regarding the determination of certain P450 detoxification. Therefore, delivery of HNF-4α genes by other systems should be considered for future studies. Recently, adeno-associated virus, which has the capacity to deliver genes to both dividing and non-dividing cells in numerous tissues, has shown significant promise in clinical trials because of its safety and delivery efficiency[35,36]. It will be a suitable strategy for the future application of HNF-4α overexpression.

COMMENTS

Background

Mesenchymal stem cells (MSCs) derived from bone marrow have the potential to differentiate into hepatocyte-like cells both in vitro and in vivo. These observations bring new hope for the possible application of cell-based therapy in severe liver diseases. However, the differentiation status of induced MSCs is poor and not sufficient for future clinical applications.

Research frontiers

The combinational action of several liver-enriched transcription factors regulates hepatic gene expression. Among them, hepatocyte nuclear factor (HNF)-4α plays a crucial role. However, the expression of HNF-4 isoforms in human hepatoma cell lines and induced MSCs has not been studied. In this study, the authors demonstrated that the overexpression of HNF-4α could enhance the hepatic differentiation of human MSCs.

Innovations and breakthroughs

This is the first report to show that the differentiation status of induced human MSCs is similar to poorly differentiated human hepatoma cell lines, all of which expressed HNF-4γ instead of HNF-4α. Overexpression of HNF-4α can significantly activate the expression of hepatic-specific genes, liver-enriched transcription factors and P450 genes and, therefore, enhance hepatic differentiation.

Applications

Overexpression of HNF-4α is a simple and convenient way to facilitate hepatic differentiation of human MSCs, and provide better cell sources for clinical application such as in vitro hepatotoxicity models for drug screening.

Peer review

This is a well-written paper that characterized human mesenchymal stem cells differentiating into hepatocyte-like cells. They found these cells express low levels of HNF-4α and high levels of HNF-4γ. Overexpression of HNF-4α induces more hepatocyte-like gene expression including p450-related genes.
REFERENCES

1 Mazaris EM, Roussos CT, Papalois VE. Hepatocyte transplantation: a review of worldwide clinical developments and experiences. Exp Clin Transplant 2005; 3: 306-315.

2 van de Kerkhove MP, Hoeskstra R, Chamuleau RA, van Gulik TM. Clinical application of bioartificial liver support systems. Ann Surg 2004; 240: 216-230.

3 Lee KD, Kuo TK, Whang-Peng J, Chung YF, Lin CT, Chou SH, Chen JR, Chen YP, Lee OK. In vitro hepatocyte differentiation of human mesenchymal stem cells. Hepatology 2004; 40: 1275-1284.

4 Snykers S, Vanhaecke T, Papeleu P, Luttun A, Jiang Y, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209: 497-499.

5 Cai J, Zhao Y, Liu Y, Ye F, Song Z, Qin H, Meng S, Chen Y, Zhou R, Song X, Guo Y, Ding M, Deng H. Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology 2007; 45: 1229-1239.

6 Snykers S, De Cock J, Rogiers V, Vanhaecke T. In vitro differentiation of embryonic and adult stem cells into hepatocytes: state of the art. Stem Cells 2009; 27: 577-605.

7 Malhi H, Irani AN, Gagandeep S, Gupta S. Isolation of human progenitor liver epithelial cells with extensive replication capacity and differentiation into mature hepatocytes. J Cell Sci 2002; 115: 2679-2688.

8 Kakiniwa S, Tanaka Y, Chinzei R, Watanabe M, Shimizu-Saito K, Hara Y, Teramoto K, Arii S, Sato C, Takase K, Yasumizu T, Teraoka H. Human umbilical cord blood as a source of transplantable hepatic progenitor cells. Stem Cells 2003; 21: 217-227.

9 Soto-Gutiérrez A, Kobayashi N, Rivas-Carrillo JD, Navarro-Alvarez N, Zhao D, Okitsu T, Noguchi H, Basma H, Tabata Y, Chen Y, Tanaka K, Narushima M, Miki A, Ueda T, Jun HS, Yoon JW, Lebkowski J, Tanaka N, Fox IJ. Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes. Nat Biotechnol 2006; 24: 1412-1419.

10 Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004; 103: 1669-1675.

11 Abdel Aziz MT, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, Ahmed HH, Rashed LA, Sadyb A, Hassouna AA, Hasan NM. Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem 2007; 40: 893-899.

12 Aurich I, Mueller LP, Aurich H, Luetzkendorf J, Tijslak K, Dollinger MM, Schorrmann W, Walldorf J, Hengstler JG, Fleig WE, Christ B. Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers. Gut 2007; 56: 405-415.

13 Kuo TK, Hung SP, Chuang CH, Chen CT, Shi YR, Fang SC, Yang VW, Lee OK. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 2008; 134: 2111-2121, 2121 e1-e5.

14 Ek M, Söderdahl T, Kühpers-Munther B, Edsbagge J, Andersson TB, Björquist P, Cotgreave I, Jernström B, Ingelman-Sundberg M, Johannsson I. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol 2007; 74: 496-503.

15 Duncan SA. Transcriptional regulation of liver development. Dev Dyn 2000; 219: 131-142.

16 Costa RH, Kalinchenco VV, Holterman AX, Wang X. Transcription factors in liver development, differentiation, and regeneration. Hepatology 2003; 38: 1331-1347.

17 Kyrmizi I, Hatzis P, Katrakili N, Tronche F, Gonzalez FJ, Talianidis I. Plasticity and expanding complexity of the hepatic transcription factor network during liver development. Genes Dev 2006; 20: 2293-2305.

18 Watt AJ, Garrison WD, Duncan SA. HNF4: a central regulator of hepatic differentiation and function. Hepatology 2003; 37: 1249-1253.

19 Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol 2001; 21: 1393-1403.

20 Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, Fraenkel E, Bell GL, Young RA. Control of pancreas and liver gene expression by HNF transcription factors. Science 2004; 303: 1378-1381.

21 Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209: 497-499.

22 Chang C, Lin Y, O-Lee TW, Chou CK, Lee TS, Liu TJ, Peng FK, Chen TY, Hu CP. Induction of plasma protein secretion in a newly established human hepatoma cell line. Mol Cell Biol 1985; 3: 1133-1138.

23 Barlow GH, Firestone SL, Robbins KC. Identification of the plasminogen activator(s) produced by the transformed liver cell line, SK-HEP-1. Thromb Res 1983; 32: 29-34.

24 Chou YC, Jeng KS, Chen ML, Liu HH, Liu TL, Chen YL, Liu YC, Hu CP, Chang C. Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method. J Virol 2005; 79: 1813-1823.

25 Zheng Y, Li J, Ou JH. Regulation of hepatitis B virus core promoter by transcription factors HNF1 and HNF4 and the viral X protein. J Virol 2004; 78: 6908-6914.

26 Tanimizu N, Miyajima A. Mechanical organization of liver development and regeneration. Int Rev Cytol 2007; 259: 1-48.

27 Drewes T, Senkel S, Holewa B, Ryffel GU. Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. Mol Cell Biol 1996; 16: 925-931.

28 LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, Parkinson A. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2000; 14: 177-188.

29 Daujat M, Pichard L, Dal et C, Larroque C, Bonfils C, Pompon D, Li D, Guzelian PS, Maurel P. Expression of five forms of microsomal cytochrome P-450 in primary cultures of rabbit hepatocytes treated with various classes of inducers. Biochem Pharmacol 1987; 36: 3597-3606.

30 Taraviras S, Mantamadiotis T, Dong-Si T, Mincheva A, Lichter P, Drewes T, Ryffel GU, Monaghan AP, Schütz G. Primary structure, chromosomal mapping, expression and transcriptional activity of murine hepatic nuclear factor 4alpha. Biochim Biophys Acta 2000; 1490: 21-32.

31 Naiki T, Nagaki M, Asano T, Kimata T, Moriwaki H. Adenovirus-mediated hepatocyte nuclear factor-4alpha overexpression maintains liver phenotype in cultured rat hepatocytes. Biochem Biophys Res Commun 2005; 335: 496-500.

32 Suet suga A, Nagaki M, Aoki H, Motohashi T, Kumasada T, Moriwaki H. Differentiation of mouse hepatic progenitor cells induced by hepatocyte nuclear factor-4 and cell transplantation in mice with liver fibrosis. Transplantation 2008; 86: 1178-1186.

33 Ma Q. Induction of CYPIA1. The AhR/DRE paradigm: transcription, receptor regulation, and expanding biological roles. Curr Drug Metab 2001; 2: 149-164.

34 Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner C, Yu L, Parkinson A, Effects...
of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. *Drug Metab Dispos* 2003; 31: 421-431

35 Richert L, Abadie C, Bonet A, Heyd B, Manton G, Alexandre E, Bachellier P, Kingston S, Pattenden C, Illouz S, Dennison A, Hoffmann S, Coecke S. Inter-laboratory evaluation of the response of primary human hepatocyte cultures to model CYP inducers - a European Centre for Validation of Alternative Methods (ECVAM) - funded pre-validation study. *Toxicol In Vitro* 2010; 24: 335-345

36 Meneses-Lorente G, Pattison C, Guyomard C, Chesné C, Heavens R, Watt AP, Sohal B. Utility of long-term cultured human hepatocytes as an in vitro model for cytochrome p450 induction. *Drug Metab Dispos* 2007; 35: 215-220

37 Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Benicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell’Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. *N Engl J Med* 2008; 358: 2240-2248

38 Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in Leber’s congenital amaurosis. *N Engl J Med* 2008; 358: 2231-2239

S- Editor Tian L L- Editor Webster JR E- Editor Ma WH